SeaCrest Wealth Management LLC Lowers Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

SeaCrest Wealth Management LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 34.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,516 shares of the company’s stock after selling 5,947 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $991,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at $42,000. Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at $48,000. Finally, M&R Capital Management Inc. increased its holdings in Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after acquiring an additional 297 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $82.99 on Thursday. The company’s 50-day moving average price is $99.26 and its 200-day moving average price is $118.18. Novo Nordisk A/S has a twelve month low of $80.05 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a market cap of $372.42 billion, a PE ratio of 26.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NVO. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.